METABOLIC DISEASE MODEL

GLP-1R Humanized Mouse Models

GLP-1R-humanized mouse models provide a human-receptor context for incretin-focused metabolic pharmacology, efficacy, exposure, and biomarker studies.

Humanization background, metabolic state, dosing strategy, study duration, and required pharmacodynamic or exposure readouts are aligned during technical review.

MODEL OVERVIEW

Human-receptor context for GLP-1 and incretin pharmacology.

GLP-1R-humanized models can support programs where species-specific receptor pharmacology matters, including candidate evaluation across obesity, glucose-control, exposure, and mechanism-linked endpoints.

Therapeutic areaObesity, Incretin biology
SpeciesMouse
Model formatGLP-1R humanized
Typical useEfficacy, PK/PD, Biomarkers
TYPICAL APPLICATIONS

What this model can support.

01

Incretin pharmacology

Evaluate GLP-1R-directed candidates in a human-receptor context when species-specific pharmacology is relevant to the program.

02

Obesity efficacy

Assess protocol-defined effects on body weight, food intake, and related metabolic outcomes.

03

Glucose-control studies

Integrate fasting glucose, glucose-tolerance, insulin, or other fit-for-purpose glycemic readouts when required.

04

PK/PD integration

Link systemic exposure and pharmacodynamic effects to efficacy or target-related readouts across dose levels and schedules.

COMMON READOUTS

Readouts selected around the study question.

Endpoints are finalized with the selected model, species or strain, treatment design, and partner laboratory before study placement.

Body weight & intake

Longitudinal body-weight and food-intake measurements according to the selected study design.

Glycemic control

Protocol-defined glucose, insulin, or glucose-tolerance endpoints when included in the program.

PK & exposure

Plasma exposure and related PK parameters for the selected candidate and dosing schedule.

PD & biomarkers

Target-related, metabolic, or mechanism-linked pharmacodynamic and biomarker measurements.

Exact host background, metabolic induction or diet, study window, dosing design, and readout package are confirmed during technical review.

STUDY DESIGN

Key factors aligned before execution.

  • Humanized GLP-1R model background
  • Candidate modality and receptor pharmacology
  • Baseline metabolic state and study entry criteria
  • Dose route, schedule, and formulation
  • Body-weight, food-intake, and glycemic endpoints
  • PK/PD, target-engagement, and biomarker requirements

Discuss Your Program

Share the compound, mechanism, development question, preferred model, and intended endpoints. We can review fit, feasibility, and the appropriate partner-laboratory route for a GLP-1R Humanized study.Required fields are marked with an asterisk(*).

What are you developing?
What should the study help evaluate?

Briefly describe what you are developing, what you want to evaluate, what material you have available, and any timeline or study requirements.

Your contact